3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Neoplasms
4
Recurrence
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinal Cord Neoplasms
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Glioma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Diseases
1
Interventions
enzalutamide
16
Magnetic Resonance Spectroscopy
16
apalutamide
15
Prednisone
12
Androgen Antagonists
12
Abiraterone Acetate
12
Specimen Handling
11
darolutamide
7
abiraterone
7
Radiotherapy
7
Pluvicto
6
Nivolumab
6
Docetaxel
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
cabazitaxel
5
Radiosurgery
5
Lutetium-177
5
Biopsy
5
radium Ra 223 dichloride
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Standard of Care
4
Lutetium
4
olaparib
3
gallium 68 PSMA-11
3
Watchful Waiting
3
Surveys and Questionnaires
3
Radiotherapy, Intensity-Modulated
3
Fulvestrant
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
abemaciclib
×
30 days
×
Clear all
No trials found.